The need for cost-effective choices to treat patients with bipolar 1 disorders including asenapine.

abstract：OBJECTIVE:The use of hemostatic agents has increased over time for all surgical procedures. The purpose of this study was to evaluate the newer topical absorbable hemostat products Surgicel * Fibrillar † and Surgicel SNoW ‡ (Surgicel advanced products, abbreviated as SAPs) compared to the older product Surgicel Origina...

journal_title：Journal of medical economics

authors： Martyn D,Kocharian R,Lim S,Meckley LM,Miyasato G,Prifti K,Rao Y,Riebman JB,Scaife JG,Soneji Y,Corral M

更新日期：2015-06-01 00:00:00

abstract：:Background: The potential impact of disease management to optimize quality of care, health outcomes, and total healthcare costs across a range of cardiac disease states is unknown. Methods: A trial-based cost-utility analysis was conducted alongside a randomized controlled trial of 335 patients with chronic, non-valvu...

journal_title：Journal of medical economics

authors： Byrnes J,Ball J,Gao L,Kai Chan Y,Kularatna S,Stewart S,Scuffham PA

更新日期：2019-09-01 00:00:00

abstract：BACKGROUND:Validation of overall survival (OS) extrapolations of immune-checkpoint inhibitors (ICIs) during the National Institute for Health and Care Excellence (NICE) Single Technology Assessment (STA) process is limited due to data still maturing at the time of submission. Inaccurate extrapolation may lead to inappr...

journal_title：Journal of medical economics

authors： Bullement A,Meng Y,Cooper M,Lee D,Harding TL,O'Regan C,Aguiar-Ibanez R

更新日期：2019-03-01 00:00:00

abstract：OBJECTIVE:The treatment of iron deficiency (ID) with ferric carboxymaltose (FCM) improves the functional class and quality of life of chronic heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF), and reduces the rate of hospitalization due to worsening CHF. This study aims to evaluate the...

journal_title：Journal of medical economics

authors： Delgado JF,Oliva J,González-Franco Á,Cepeda JM,García-García JÁ,González-Domínguez A,Garcia-Casanovas A,Jiménez Merino S,Comín-Colet J

更新日期：2020-10-30 00:00:00

abstract：OBJECTIVE:To estimate the economic implications of introducing dabigatran etexilate ('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial fibrillation based on results of the RE-LY trial. METHODS:The lifetime cost and outcomes of dabigatran and warfarin were estimated using a previous...

journal_title：Journal of medical economics

authors： Langkilde LK,Bergholdt Asmussen M,Overgaard M

更新日期：2012-01-01 00:00:00

abstract：AIMS:This study aimed to evaluate the economic value for leuprorelin acetate 6-month depot compared with leuprorelin acetate 3-month depot from a societal perspective in Japanese prostate cancer patients. METHODS:The cost analysis estimated the reduction in direct and indirect costs as well as intangible costs saved b...

journal_title：Journal of medical economics

authors： Goto R,Uda A,Hiroi S,Iwasaki K,Takashima K,Oya M

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:In the last decade, the number of new agents, including monoclonal antibodies, being developed to treat metastatic colorectal cancer (mCRC) increased rapidly. While improving outcomes, these new treatments also have distinct and known safety profiles with toxicities that may require hospitalizations. However...

journal_title：Journal of medical economics

authors： Overbeek JA,Zhao Z,van Herk-Sukel MP,Barber BL,Gao S,Herings RM

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVE:The economic implications from the US Medicare perspective of adopting alternative treatment strategies for acute bacterial skin and skin structure infections (ABSSSIs) are substantial. The objective of this study is to describe a modeling framework that explores the impact of decisions related to both the lo...

journal_title：Journal of medical economics

authors： Revankar N,Ward AJ,Pelligra CG,Kongnakorn T,Fan W,LaPensee KT

更新日期：2014-10-01 00:00:00

abstract：OBJECTIVE:Basal insulin analogs are well established in the treatment of type 1 diabetes in Germany. However, little is known about their economic impact. The aim of this study for an adult population was to compare, from the perspective of the Statutory Health Insurance (SHI), the cost effectiveness of the long-acting...

journal_title：Journal of medical economics

authors： Pfohl M,Schädlich PK,Dippel FW,Koltermann KC

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVE:To assess patient characteristics, treatment patterns, and healthcare resource utilization (HRU)/costs of individuals treated for neuroendocrine tumors (NETs) in the US. METHODS:Using a US administrative claims database, this study identified commercially-insured adults newly diagnosed with carcinoid tumors ...

journal_title：Journal of medical economics

authors： Chuang CC,Bhurke S,Chen SY,Brulais S,Gabriel S

更新日期：2015-02-01 00:00:00

abstract：PURPOSE:The Czech Republic is faced with making choices between pharmaceutical products, including depot injectable antipsychotics. A pharmacoeconomic analysis was conducted to determine the cost-effectiveness of atypical depots. METHODS:An existing 1-year decision-analytic framework was adapted to model drug use in t...

journal_title：Journal of medical economics

authors： Einarson TR,Zilbershtein R,Skoupá J,Veselá S,Garg M,Hemels ME

更新日期：2013-09-01 00:00:00

abstract：OBJECTIVES:To assess the costs of severe hypoglycaemic events (SHEs) in diabetes patients in Germany, Spain and the UK. METHODS:Healthcare resource use was measured by surveying 639 patients aged ≥ 16 years, receiving insulin for type 1 (n=319) or type 2 diabetes (n=320), who experienced ≥ 1 SHE in the preceding year....

journal_title：Journal of medical economics

authors： Hammer M,Lammert M,Mejías SM,Kern W,Frier BM

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVE:In the phase III SECURE trial, isavuconazole was non-inferior to voriconazole for all-cause mortality for the primary treatment of invasive mold disease (IMD) caused by Aspergillus spp. and other filamentous fungi. This analysis assessed whether hospital resource utilization was different between patients tre...

journal_title：Journal of medical economics

authors： Horn D,Goff D,Khandelwal N,Spalding J,Azie N,Shi F,Franks B,Shorr AF

更新日期：2016-07-01 00:00:00

abstract：:Aims: Estimate the direct costs of high-risk patients presenting with coronary artery disease (CAD) or peripheral artery disease (PAD) in France.Materials and methods: This retrospective cohort study used a representative claims database, the "Echantillon Généraliste de Bénéficiaires" (EGB), to identify patients prese...

journal_title：Journal of medical economics

authors： Emery C,Torreton E,Briere JB,Evers T,Fagnani F

更新日期：2020-05-01 00:00:00

abstract：OBJECTIVE:The past few decades have been marked by a bold increase in national health spending across the globe. Rather successful health reforms in leading emerging markets such as BRICS reveal a reshaping of their medical care-related expenditures. There is a scarcity of evidence explaining differences in long-term m...

journal_title：Journal of medical economics

authors： Jakovljevic MM

更新日期：2016-01-01 00:00:00

abstract：OBJECTIVE:To estimate health-related quality of life (HRQoL) in non-growth hormone deficient (GHD) small for gestational age (SGA) children before and after growth hormone (GH) treatment to adult height (AH). METHODS:This was a multicentre, two-arm trial. Following an initial 2-year double-blind study period, patients...

journal_title：Journal of medical economics

authors： Bannink E,Djurhuus CB,Christensen T,Jøns K,Hokken-Koelega A

更新日期：2010-01-01 00:00:00

abstract：OBJECTIVE:To quantify the health economic impact of managing cow milk allergy (CMA) in South Africa, from the perspective of healthcare insurers in both the private and public sectors and parents/carers of CMA sufferers. METHODS:A decision model depicting the management of CMA in South Africa was constructed, using in...

journal_title：Journal of medical economics

authors： Sladkevicius E,Guest JF

更新日期：2010-01-01 00:00:00

abstract：INTRODUCTION:Myelofibrosis is a non-frequent chronic myeloproliferative Philadelphia-negative chromosome neoplasm. It is a heavy incapacitating orphan disease and associated with high morbidity and mortality. In this context, indirect and non-medical costs are expected to be high. The main objective of this project is ...

journal_title：Journal of medical economics

authors： Gimenez E,Besses C,Boque C,Velez P,Kerguelen A,Cervantes F,Ferrer-Marin F,Perez-Encinas M,Rodriguez M,Gonzalez JD,Calzada R,Hernandez-Boluda JC

更新日期：2014-06-01 00:00:00

abstract：:Objectives: Aging populations are contributing to an increased volume of osteoporotic fractures. The goals of this study were to (1) develop a scorecard on epidemiological burden, policy framework, service provision, and service uptake for osteoporosis in Saudi Arabia and (2) estimate the direct costs of managing oste...

journal_title：Journal of medical economics

authors： Aziziyeh R,Garcia Perlaza J,Saleem N,Sadat-Ali M,Elsalmawy A,McTavish RK,Duperrouzel C,Cameron C

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:EOX (epirubicin, oxaliplatin, Xeloda; capecitabine) and FOLFOX4 (5-fluorouracil (5-FU), leucovorin, oxaliplatin) are the common chemotherapy regimens used in the treatment of advanced gastric cancer (aGC) in Hong Kong. This study aimed to compare the costs of these therapies for aGC patients from both the he...

journal_title：Journal of medical economics

authors： Zhou KR,Cheng A,Ng WT,Kwok TY,Yip EY,Yao R,Leung PY,Lee VW

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:Inhibitor development to factor VIII (FVIII) hemophilia therapy results in increased complications and substantial economic costs. The SIPPET study, the first randomized controlled trial to compare the immunogenicity of plasma-derived FVIII (pdFVIII)/von Willebrand factor (VWF) and recombinant-DNA-derived FV...

journal_title：Journal of medical economics

authors： Neufeld EJ,Sidonio RF Jr,O'Day K,Runken MC,Meyer K,Spears J

更新日期：2018-08-01 00:00:00

abstract：AIMS:Depression is the most frequent comorbidity reported among patients with rheumatoid arthritis (RA). Comorbid depression negatively impacts RA patients' health-related quality-of-life, physical function, mental function, mortality, and experience of pain and symptom severity. The objective of this study was to asse...

journal_title：Journal of medical economics

authors： Li N,Chan E,Peterson S

更新日期：2019-04-01 00:00:00

abstract：AIM:Disease-modifying therapies (DMTs) impact the natural history of relapsing forms of multiple sclerosis (RRMS) by reducing annual relapse rates and slowing disability progression. The effect of DMTs on indirect costs has not been consistently explored in cost-effectiveness studies thus far. The value to patients of ...

journal_title：Journal of medical economics

authors： Frasco MA,Shih T,Incerti D,Diaz Espinosa O,Vania DK,Thomas N

更新日期：2017-10-01 00:00:00

abstract：:Aims: This study aimed to examine the long-term clinical and economic burden of adults with congenital heart disease (ACHD) in Hong Kong. Methods: It retrospectively analyzed 336 consecutive ACHD patients who attended the Adult Congenital Heart Clinic between January 1, 2009 and December 31, 2014. Direct medical costs...

journal_title：Journal of medical economics

authors： Lee VWY,Yan BP,Fong TMC,Fung AKP,Cheng FWT

更新日期：2019-08-01 00:00:00

abstract：AIM:The aim of this analysis was to investigate total healthcare costs, HbA1c, and weight changes over a 36-month period in patients with type 2 diabetes initiated on NPH or long-acting insulin analogs. METHODS:Electronic patient data from 479 general practices in the UK (THIN database) were examined for new users of ...

journal_title：Journal of medical economics

authors： Idris I,Gordon J,Tilling C,Vora J

更新日期：2015-04-01 00:00:00

abstract：OBJECTIVE:Iso-osmolar Iodixanol is associated with a lower rate of contrast-induced acute kidney injury (CI-AKI) in patients at increased risk compared to low-osmolar contrast media (LOCM). The aim of this study was to assess the financial consequences of CI-AKI risk reduction in patients undergoing coronary angiograph...

journal_title：Journal of medical economics

authors： De Francesco M,Ronco C,Wacinski PJ,Wessely R,Hernández F,Lamotte M

更新日期：2016-01-01 00:00:00

abstract：OBJECTIVE:Epilepsy surgery is one of the most effective treatments in modern medicine. Yet, it remains largely under-utilized, in spite of its proven efficacy. The referrals for epilepsy surgery are often delayed until it is too late to prevent the detrimental psychosocial effects of refractory seizures. The reluctance...

journal_title：Journal of medical economics

authors： Edwards JC,Sobel RS,Bonilha L

更新日期：2018-05-01 00:00:00

abstract：:Aim: To estimate the cost-effectiveness of atezolizumab compared with docetaxel and nivolumab for the treatment of advanced non-small cell lung cancer (NSCLC), as a second-line treatment, in a French setting.Materials and methods: A three-state partitioned-survival model was developed (progression-free survival, post-...

journal_title：Journal of medical economics

authors： Marine S,Stéphane R,Nicolas P,Felizzi F,Paracha N,Benjamin M,Perol M

更新日期：2020-05-01 00:00:00

abstract：INTRODUCTION:The patient cost burden of oral anticancer medicines has been associated with prescription abandonment, delayed treatment initiation, and poorer health outcomes in the US. Since 2011, several small molecule tyrosine kinase inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC...

journal_title：Journal of medical economics

authors： Seetasith A,Wong W,Tse J,Burudpakdee C

更新日期：2019-05-01 00:00:00

abstract：:Aims: OnabotulinumtoxinA is recommended by NICE for the treatment of chronic migraine. This economic evaluation provides updated estimates of the cost-effectiveness of onabotulinumtoxinA for chronic migraine using new utility estimates in an existing model structure.Methods: A previously published model was revised to...

journal_title：Journal of medical economics

authors： Hollier-Hann G,Curry A,Onishchenko K,Akehurst R,Ahmed F,Davies B,Keyzor I

更新日期：2020-01-01 00:00:00